Insmed Inc. to Announce 2006 Third Quarter Financial Results.Conference Call and Webcast Friday, November 3, 2006 at 11:00 a.m. (ET) RICHMOND, Va. -- Insmed (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :INSM INSM Initiative Neue Soziale Marktwirtschaft (German) INSM Integrated Network and Systems Management ) announced today that it will release its 2006 third quarter financial results on Friday, November 3, 2006 at 11:00a.m. (ET). The Company will host a conference call on Friday, November 3 at 11:00 a.m. Eastern Time to discuss the financial results and provide a business update. Interested investors can listen to the call over the internet from Insmed's investor relations website at www.insmed.com or by dialling 800-361-0912 (domestic) or 913-981-5559 (international). A telephonic replay of the call will be available for one week at 888-203-1112 (domestic) or 719-457-0820 (international), pass code: 4663784. A web replay of the call will be available through the corporate website beginning at 6:00 p.m. About Insmed Incorporated Insmed is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com. The company's leading product, IPLEX, was approved as an orphan drug by the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. in December 2005 for the treatment of growth failure in children with severe primary IGF-I IGF-I see somatomedin C. IGF-I Insulin-like growth factor I, somatomedin-C A polypeptide hormone structurally similar to proinsulin, synthesized in the liver and fibroblasts, giving fibroblasts a paracrine function; serum levels correlate with deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. About IPLEX IPLEX, a complex of recombinant human IGF-I and its binding protein IGFBP-3 (rhIGF-I/rhIGFBP-3), is the only once-daily IGF-I replacement therapy. It is also the only FDA-approved therapy that provides both IGF-I and IGFBP-3 to treat children with severe primary IGFD. The drug, launched during the second quarter of 2006, is also being investigated for various other indications with unmet medical needs, including extreme insulin resistance, myotonic muscular dystrophy Noun 1. myotonic muscular dystrophy - a severe form of muscular dystrophy marked by generalized weakness and muscular wasting that affects the face and feet and hands and neck; difficult speech and difficulty with the hands that spreads to the arms and shoulders and and HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. Associated Adipose adipose /ad·i·pose/ (ad´i-pos) 1. fatty. 2. the fat present in the cells of adipose tissue. ad·i·pose adj. Of, relating to, or composed of animal fat; fatty. Redistribution Syndrome (HARS). About the Condition Severe primary IGFD is a genetic or acquired condition in which patients do not generate sufficient quantities of insulin-like growth factor-I (IGF-I) due to defect in the growth hormone (GH) receptor/IGF-I pathway. Gene mutations leading to growth failure due to IGF-I deficiency have been identified in the growth hormone receptor Growth hormone receptor is a protein which acts as a receptor for somatotropin. Defects in the gene are associated with Laron syndrome. External links
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion